Moderna Inc
Change company Symbol lookup
Select an option...
MRNA Moderna Inc
MUSA Murphy Usa Inc
SCL Stepan Co
GRWG GrowGeneration Corp
ROG Rogers Corp
ALB Albemarle Corp
DD Dupont De Nemours Inc
SMG Scotts Miracle-Gro Co
MTX Minerals Technologies Inc
HUN Huntsman Corp
Go

Health Care : Biotechnology | Large Cap Blend
Company profile

Moderna, Inc. is a biotechnology company that is focused on creating a transformative medicines based on messenger ribonucleic acid (mRNA), to improve the lives of patients. The Company’s mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a range of spectrum of diseases. It is developing vaccines and therapeutics for infectious diseases, immuno-oncology, rare diseases, autoimmune and cardiovascular diseases, independently and with its strategic collaborators. The Company develops technologies that enable the development of mRNA medicines for diverse applications. It has created modalities, including prophylactic vaccines, systemic secreted and cell surface therapeutics, cancer vaccines, intratumoral immuno-oncology, and systemic intracellular therapeutics. The Company develops technologies that enable the development of mRNA medicines.

Closing Price
$176.40
Day's Change
-0.41 (-0.23%)
Bid
--
Ask
--
B/A Size
--
Day's High
179.14
Day's Low
173.41
Volume
(Light)
Volume:
1,221,141

10-day average volume:
3,746,478
1,221,141

Health official says updated COVID-19 boosters likely to be available in weeks for elementary school-age children

7:20 am ET September 23, 2022 (MarketWatch)
Print

Jaimy Lee

Plus, Moderna is 'eager' to sell its COVID-19 shot in China, and U.S. cases continue to decline.

A Food and Drug Administration official said this week that updated COVID-19 boosters for 5- to 11-year-olds will be authorized in the coming weeks, according to ABC News.

The new boosters developed by BioNTech (BNTX)/Pfizer (PFE) and Moderna (MRNA) protect against the original strain of the virus as well as the newer BA.4 and BA.5 subvariants, which make up about 85% of all cases worldwide right now.

"I'm confident that we're only a matter of weeks away," Dr. Peter Marks, director of the FDA's Center for Biologics Evaluation and Research, said Tuesday at an event.

The shots are expected to roll out to different age groups much as have been seen before. They will likely be available first for 5- to 11-year-olds first and then for younger children.

That said, COVID-19 vaccine uptake for children has been low. Only about 9.3 million children younger than 12 years old are fully vaccinated. There are about 43 million children in the U.S. who are 10 years old or younger.

Other COVID-19 news to know:

-Jaimy Lee

	

(END) Dow Jones Newswires

September 23, 2022 07:20 ET (11:20 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.